Welcome Message

MDM2 and its homolog MDM4 (also known as MDMX) are the two most important negative regulators of the tumor suppressor p53 by acting as an E3 ubiquitin ligase complex to promote p53 degradation and physically binding to inhibit the p53’s transcriptional functions. These proteins are overexpressed in about 30% of human cancers. Overexpression of MDM2/MDM4 not only inhibits p53 functions but also shows p53-independent oncogenic activities. Inhibitors against MDM2 and MDM4 have been developed to reactivate wild-type p53 in tumors, some of which are currently in clinical trials.

The MDM2 Workshop has been held alternately in the U.S. and Europe every two to three years to bring together the p53/MDM2 field, present the latest research, facilitate collaboration, and exchange reagents. The 10th International MDM2 Workshop will be held in Japan, for the first time in Asia. Notably, this is the first MDM2 Workshop since the COVID-19 pandemic started. The Workshop will be held at the auditorium of the National Cancer Center Research Institute (NCCRI) in Tokyo, Japan, on October 15-18, 2023.

The meeting will be co-organized by:

Rieko Ohki

(NCCRI, Tokyo, Japan)

Koji Itahana

(Duke-NUS Medical School, Singapore)

Tomoo Iwakuma

(Children’s Mercy Research Institute, MO, USA)

PROGRAM

On the first day of the workshop, we are planning a special symposium on MDM2 to discuss the historical discoveries on MDM2 and the future directions of MDM2 research.

This symposium offers a fascinating opportunity for many researchers to hear directly from the actual discoverers about the breakthroughs that are featured in textbooks such as "the biology of cancer.” Furthermore, on the third day, we will conduct special sessions aimed at bridging the rapidly advancing field of cancer immunology with the MDM2/MDM4/p53 field.

Day 1: October 15, 2023 (Sunday)

2:30 – 4:00pm

Registration – Lobby

4:00 – 4:10pm

Welcome and opening remarks (Rieko Ohki, Koji Itahana, Tomoo Iwakuma)

4:10 – 4:20pm

Welcome talk by Hitoshi Nakagama, National Cancer Center

Opening Session 1: Celebrating the discovery of MDM2 and its functions

4:20 – 4:50pm

S1: Donna George
Gene amplification and the discovery of MDM2

4:50 – 5:20pm

S2: Jamil Momand & Gerry Zambetti
Discovery of Mdm2 as an inhibitor of p53

5:20 – 5:55pm

S3: Guillermina Lozano
The physiological consequences of too little or too much Mdm2

5:55 – 6:10pm

Break

6:10 – 6:40pm

S4: Binh Vu
Discovery of Nutlins

6:40 – 7:15pm

S5: Matthias Dobbelstein
MDM2/MDM4 – sensor, effector and target

7:45 –9:45pm

Welcome Party at SCHMATZ (https://www.schmatz.jp/)

Day 2: October 16, 2023 (Monday)

8:30 – 8:40am

Welcome talk by Hiroyuki Mano, National Cancer Center Research Institute

8:40 – 9:15am

S6: Carol Prives (Keynote talk)
p53-independent roles of Mdm2 and MdmX in cell growth, cell death and metastasis

Session 2: Novel function and regulation of MDM2/MDM4/p53 (part 1)

9:15 – 9:40am

S7: Wei Gu
The complexity of p53-mediated tumor suppression and its regulation by Mdm2 and Mdmx

9:40 – 10:00am

S8: Dawn Chandler
Alternative splicing of MDM2: Mechanisms and therapeutic targets

10:00 – 10:20am

S9: Tomoo Iwakuma
APOBEC4, a novel target of p53, is required for MDM2 antagonist-mediated tumor suppression

10:20 – 10:35am

ST1: Alexandra Indeglia
PADI4 is a key epigenetic regulator of the p53 pathway and tumor suppression

10:35 – 11:05am

COFFEE BREAK – Lobby

Session 3: p53-independent functions of MDM2/MDM4

11:05 – 11:25am

S10: Lindsey Mayo
The tumor suppressor pVHL represses signaling pathways that increase Mdm2

11:25 – 11:40am

ST2: Laetitia Linares
MDM2 regulates a metabolic crosstalk between liposarcoma and muscle sustains tumor growth

11:40 – 11:55am

ST3: Rasoul Pourebrahim
P53-independent role of Mdm2 in metabolic maintenance of hematopoietic stem cells via mevalonate pathway

11:55 – 12:10pm

ST4: Carla Finkielstein
Targeting of the core clock mechanism by MDM2 dictates circadian oscillations

12:10 – 2:10pm

LUNCH & Poster (1:00-2:00pm) Session – at NCCRI, Tokyo Poster presenters; please be at the poster session between 1:00-2:00pm

Special sessions: Cancer Immunology

2:10 – 2:50pm

S11: Tadatsugu Taniguchi (Keynote talk)
Interferons, p53/MDM2 and DAMPs; discovering the underpinnings of immunity

Session 4: MDM2/MDM4/p53 in immunity and tumor immunity

2:50 – 3:15pm

S12: Galina Selivanova
MDM2 inhibitors trigger p53-dependent interferon response thus promoting anti-cancer immunity

3:15 – 3:35pm

S13: Koji Itahana
The novel role of the MDM2-p53 pathway in host defense by regulating iron metabolism in macrophages

3:35 – 3:50pm

ST5: Wenwei Hu
p53 suppresses MHC-II presentation by the intestinal epithelium to protect intestinal stem cells and mucosal epithelium upon radiation

3:50 – 4:05pm

ST6: Amy Hui Ping Khor
p53 in the regulation of the innate immune response and gut microbiome

4:05 – 4:35pm

COFFEE BREAK – Lobby

Session 5: MDM2/MDM4/p53 in tumor immunity and microenvironments, and immunotherapy

4:35 – 5:00pm

S14: Yinon Ben-Neriah
Immunity in acute myeloid leukemia: where the immune response and targeted therapy meet

5:00 – 5:25pm

S15: Luis Martinez
p53 engages the cGAS/STING pathway for tumor suppression

5:25 – 5:45pm

S16: Masanobu Oshima
Gain-of-function mutant p53 for activin signaling-induced epithelial-to-mesenchymal transition (EMT)

5:45 – 6:05pm

S17: Susumu Goyama
Targeting TP53 for acute myeloid leukemia and its relation to tumor immunity

6:05 – 6:20pm

ST7: Yong Li
Targeting missense p53 mutants using AI, antibodies, and vaccines

Day 3: October 17, 2023 (Tuesday)

8:30 – 9:05am

S18: Sir. David Lane (Keynote talk)
Design-rules for stapled peptides with on-target in vivo activity: Application to Mdm2/X antagonists

Session 6: Animal models of MDM2/MDM4/p53

9:05 – 9:30am

S19: Laura Attardi
p53 repurposes an injury repair program during lung cancer suppression

9:30 – 9:55am

S20: James Manfredi
Mdm2 regulates gene expression by p53 in vivo through both canonical and non-canonical modes of gene occupancy

9:55 – 10:10am

ST8: Shunbin Xiong
The amino terminus of Mdm4 contributes to p53 inhibition in vivo

10:10 – 10:25am

ST9: Masataka Yokoyama
Protective role of endothelial p53 in stress induced vascular malignancy

10:25 – 10:55am

COFFEE BREAK – Lobby

Session 7: Novel function and regulation of MDM2/MDM4/p53 (part 2)

10:55 – 11:20am

S21: Jill Bargonetti
A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 to chromatin

11:20 – 11:40am

S22: Chandra Verma
Mechanisms of phosphorylations along the MDM2-MDMX-p53 axis

11:40 – 12:00pm

S23: Rieko Ohki
A novel extrinsic apoptosis pathway regulated via the p53-p53PAD7-Hippo-YAP/TAZ axis

12:00 – 12:15pm

ST10: Zhaohui Feng
The E3 ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain-of-function in cancer

12:15 – 2:15pm

LUNCH & Poster (1:00-2:00pm) Session – at NCCRI, Tokyo
Poster presenters; please be at the poster session between 1:00-2:00pm

Session 8: Controls of p53 signaling by MDM2/MDM4 and other proteins

2:15 – 2:40pm

S24: Hua Lu
Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from MDM2-mediated proteolytic degradation

2:40 – 3:00pm

S25: Manabu Kurokawa
An E3 ligase for Mdm2 and Mdm4

3:00 – 3:15pm

ST11: Keiko Kawauchi
Emerging roles of actin in p53-dependent DNA damage responses

3:15 – 3:30pm

ST12: Vivi Kasim
Identification and application of new regulators of MDM2-p53 complex integrity

3:30 – 3:45pm

ST13: Vanesa Olivares-Illana
The E3 ubiquitin ligase and translation factor activities of MDM2 control the expression levels of p53 and RB tumour suppressors

3:45 – 4:15pm

BREAK & Discussion – Lobby

Session 9: Functions of p53, mutant p53, p53 family, and p53 isoforms

4:15 – 4:40pm

S26: Kanaga Sabapathy
p44, the amino-terminal lacking isoform of p53, is dispensable for tumor suppression but regulates male fertility in mice

4:40 – 5:00pm

S27: Marco Candeias
Alternative translation in p53 mRNA: the switch from tumor suppressor to oncogene?

5:00 – 5:15pm

ST14: Yu Chen
Modified p53 pathway promotes the malignant progression of PanNET by activating the Akt pathway and altering metabolism

5:15 – 5:30pm

ST15: Mizuho Nakayama
Wnt signaling activation in colon cancer cells by gain-of-function mutant p53 through COX-2/PGE2 pathway

5:30 – 5:45pm

ST16: Marco Napoli
Nutlin-3a/pramlintide combination as a novel therapeutic strategy to target the p53 pathway in cancer

Break

7:00 – 9:30pm

WORKSHOP DINNER at Berth One Tokyo (http://www.berth1.tokyo)

Day 4: October 18, 2023 (Wednesday)

Session 10: Development of therapies targeting MDM2/MDM4/p53 (part1)

8:30 – 8:55am

S28: Christine Eischen
New Insights into Targeted Mdm2 Degradation

8:55 – 9:15am

S29: Takafumi Koyama
Clinical Utility and Emerging Resistance Mechanisms of Milademetane, an MDM2 Inhibitor, for MDM2-amplified Intimal Sarcoma

9:15 – 9:30am

ST17: Shruti Bhatt
Targeting non-transcriptional function of TP53 to overcome therapy resistance in leukemia

9:30 – 9:45am

ST18: Carlotta Giorgi
Innovative treatment options for cancers harboring p53 alterations by antagonizing the P2X7R

9:45 – 10:10pm

BREAK & Discussion – Lobby

Session 11: Development of therapies targeting MDM2/MDM4/p53 (part 2)

10:10 – 10:35am

S30: Jiandong Chen
Hypothermia treatment of tumors with temperature sensitive p53 mutations

10:35 – 10:50am

ST19: James A DeCaprio
Activity of MDM2 degrader KTX-049 in Merkel cell carcinoma

10:50 – 11:05am

ST20: Diana Spiegelberg
Targeting mutant p53: Evaluation of novel anti-p53R175H monoclonal antibodies as agents for molecular imaging

11:05 – 11:20am

ST21: Alejandro Parrales
Simultaneous ROS-mediated DNA damage and ATM inhibition induce p53 synthetic lethality

11:20 – 12:05pm

S31: Arnold Levine (Final Remarks)
Exploring the genetic and molecular basis of differences in multiple myeloma of individuals of African and European descent

12:05 –

Boxed LUNCH and Departure/Optional tour

1:20pm: Optional Conference Tour

1:20pm dispatch / 1:30pm departure

National Cancer Center (Tsukiji)

2:00-3:00pm

Imperial Palace
Sakashimon Gate - Nijubashi Bridge - Statue of Masanari Kusunoki

3:40-4:40pm

Walking & Shopping
Asakusa Kannon and Nakamise Shopping Street

5:00-6:20pm

Tokyo Sky Tree [TEMBO DECK]
View from 350m above ground

Around 7:00pm

Return to National Cancer Center (Tsukiji)

SPEAKERS

Highlighted speakers

(Alphabetized by last name)

David Lane

(Karolinska Institute, Sweden)

Arnold Levine

(Institute for Advanced Study, US)

Carol Prives

(Columbia University, US)

Tadatsugu Taniguchi

(The University of Tokyo, Japan)

Opening session keynote speakers

(Alphabetized by last name)

Matthias Dobbelstein

(University Medical Center Göttingen, Germany)

Donna George

(University of Pennsylvania, US)

Guillermina Lozano

(MD Anderson Cancer Center, US)

Jamil Momand

(California State University, Los Angeles, US)

Binh Vu

(PMV Pharmaceuticals, US)

Gerard Zambetti

(St. Jude Children’s Research Hospital, US)

Other speakers

(Alphabetized by last name)

Laura Attardi 

(Stanford University School of Medicine, US)

Jill Bargonetti

(City University of New York, US)

Yinon Ben-Neriah

(Hebrew University-Hadassah Medical School, Israel)

Marco Candeias

(Kyoto University, Japan)

Dawn Chandler 

(The Ohio State University, US)

Jiandong Chen

(Moffitt Cancer Center, US)

Christine M. Eischen 

(Thomas Jefferson University, US)

Susumu Goyama

(The University of Tokyo, Japan)

Wei Gu

(Columbia University, US)

Koji Itahana

(Duke-NUS Medical School, Singapore)

Tomoo Iwakuma

(Children's Mercy Research Institute, US)

Takafumi Koyama

(National Cancer Center Hospital, Tokyo, Japan)

Manabu Kurokawa

(Kent State University, US)

Hua Lu

(Tulane University, US)

James Manfredi

(Icahn School of Medicine at Mount Sinai, US)

Luis Martinez

(Stony Brook University, US)

Lindsey Mayo

(Indiana University School of Medicine, US)

Rieko Ohki

(National Cancer Center Research Institute, Japan)

Masanobu Oshima

(Kanazawa University, Japan)

Kanaga Sabapathy

(National Cancer Center Singapore, Singapore)

Galina Selivanova

(Karolinska Institutet, Sweden)

Chandra Verma 

(A*STAR Bioinformatics Institute, Singapore)

REGISTRATION

ACCOMMODATIONS

There are also other hotels near the venue listed below.
You can visit the hotel website and make a reservation by yourself.

• HOTEL VISTA TOKYO TSUKIJI (3 min walk)
  
• VIA INN HIGASHI-GINZA (5 min walk)
  
• Agora Tokyo Ginza (5 min walk)
  
• Tabist GINZA (6 min walk)
  
• KOKO HOTEL Tsukiji Ginza (9 min walk)
  
• HOTEL GRACERY GINZA (11 min walk)
  
• Ibis Styles Tokyo Ginza (11 min walk)
  

Conference coordinator
Rieko Ohki
Secretariat    regn@10thmdm2.jp (in English)
開催事務局    secjp@10thmdm2.jp (日本語)

Restaurant information can be found in the following link:
https://www.google.com/maps/d/embed?mid=1VajJC3FUpXeQTNrJvCWAJTv4sKFq1no&ehbc=2E312F

VENUE

The workshop will be held in the auditorium of the National Cancer Center Research Institute (NCCRI) in Tokyo, Japan.

Directions to the NCCRI

Map of the NCCRI campus

ORGANIZING COMMITTEE

HOST INSTITUTION

National Cancer Center Research Institute (NCCRI), Tokyo, Japan

ORGANIZERS

Rieko Ohki

National Cancer Center Research Institute

Koji Itahana

Duke-NUS Medical School, Singapore

Tomoo Iwakuma

Children's Mercy Research Institute, USA

ORGANIZING COMMITTEE

Co-organizer
Hiroyuki Mano

National Cancer Center Research Institute

Advisor
Hitoshi Nakagama

National Cancer Center

Masanobu Oshima

Kanazawa University

Tomoaki Tanaka

Chiba University

Koichi Matsuda

The University of Tokyo

Koji Okamoto

Teikyo University

Hirofumi Arakawa

National Cancer Center Research Institute

Takashi Tokino

Sapporo Medical School

Manabu Kurokawa

Kent State University

Koichi Kawahara

Kagoshima University

Marco Candeias

Kyoto University

Chizu Tanikawa

The University of Tokyo

INTERNATIONAL ORGANIZING COMMITTEE

INTERNATIONAL ORGANIZING COMMITTEE

Arnold Levine

Institute for Advanced Study, US

David Lane

Karolinska Institute, Sweden

Carol Prives

Columbia University, US

Guillermina Lozano

MD Anderson Cancer Center, US

Karen Vousden

The Francis Crick Institute, UK

Wei Gu

Columbia University, US

James Manfredi

Icahn School of Medicine at Mount Sinai, US

Laura Attardi

Stanford University School of Medicine, US

Ygal Haupt

Peter MacCallum Cancer Center, Australia

Yanping Zhang

University of North Carolina at Chapel Hill, US

Hua Lu

Tulane University, US

Jiandong Chen

Moffitt Cancer Center, US

Christine Eischen

Thomas Jefferson University, US

Ute Moll

Stony Brook University, US

Matthias Dobbelstein

University Medical Center Göttingen, Germany

Pierre Hainaut

Institute for Advanced Biosciences, France

SPONSORS

• PMV Pharma
• International Medical Research Foundation
• The Molecular Biology Society of Japan
• The Uehara Memorial Foundation
• The Naito Foundation
• Chugai Pharmaceutical Co. Ltd
• The Novartis Foundation
• Duke-NUS Medical School, Singapore
• University of Kansas Cancer Center
• Children’s Mercy Research Institute
• Chugai Foundation for Innovative Drug Discovery Science